How to Talk About Overmedication Without Alarming Anyone
There’s a number sitting in your pharmacy claims data right now. It’s not dramatic. It doesn’t flash red. But it tells a story about the members on your plan who are managing five, eight, maybe ten medications at once — and nobody has looked at the full picture.
That’s polypharmacy. As a broker or benefits leader, it can feel tricky to bring this up. How do you frame a clinical problem in a benefits conversation without sounding accusatory?
Here’s the answer: you don’t lead with alarm. Start with data and let the numbers do the work.
This Is Already a Business Problem
Polypharmacy, defined as five or more concurrent prescriptions, affects roughly 42% of American adults over 65, with 12% managing ten or more medications at the same time. That’s a significant slice of health plans.
The cost signature is substantial. Research published in The American Journal of Cardiology found that older adults with polypharmacy carried nearly double the total healthcare expenditure of those without it driven not just by pharmacy spend, but by the downstream medical costs that follow: adverse drug reactions, hospitalizations, readmissions, and office visits that wouldn’t otherwise happen.
A 2025 study in BMC Geriatrics confirmed the pattern using nationally representative data spanning 2018–2021: polypharmacy was independently associated with meaningfully higher healthcare expenditures after controlling for demographics and comorbidities. More drugs, more spend even when you account for why they’re taking more drugs.
The Hidden Waste Most Plans Never See
The clinical risk of polypharmacy is well-documented. The financial waste is less visible and that’s exactly where brokers can add value.
Oversupply is one of the most underappreciated contributors. Early refills and automatic dispensing keep members on medications longer than clinically necessary. A recent Wall Street Journal analysis found that Medicare patients received roughly $3 billion in excess drugs from pharmacies, with mail-order pharmacies (representing ~9% of Medicare prescriptions) accounting for 37% of the excess dispensing.
This is the crux of why polypharmacy is hard to catch from a payer’s perspective: it looks fine until it doesn’t. The fills are legitimate. The timing is compliant. But the cumulative picture includes duplicate therapies, adverse drug interactions, and medications that are no longer clinically indicated.
Research presented at the Academy of Managed Care Pharmacy 2025 conference reinforced this, showing that AI-driven medication management platforms that proactively identify high-risk polypharmacy patients can reduce healthcare utilization and costs significantly before adverse events drive the claims.
More Drugs ≠ Better Care
This is the reframe that makes the conversation possible.
The members on your plan who are most medicated are often the ones receiving the most fragmented care. They see multiple specialists. Each visit may generate a new prescription. No single provider has visibility into the full medication list. The result isn’t better outcomes, it’s just risk compounding out of control that no one intended and few are managing.
A 2025 narrative review in ScienceDirect said clearly that raising physician awareness of polypharmacy is necessary, but insufficient on its own. What moves the needle is structured medication review, deprescribing protocols, and clinical decision support that routes information to the right person at the right moment: the prescriber.
That last point matters. The physician is the only actor in this system who can safely reassess a medication list. Unfortunately, most physicians don’t have a complete picture of what their patients are taking.
How to Raise It: The Broker’s Playbook
The conversation doesn’t have to start with the word “overmedication.” It can start with a question your client is already asking: Why is our pharmacy spend trending up even though our population hasn’t changed?
From there, the path is straightforward.
Lead with measurement, not conclusions.
Polypharmacy flags are visible in claims data. Members on five or more concurrent medications can be identified, their drug combinations can be assessed for interaction risk and duplication, and the financial profile can be quantified. Starting with “here’s what the data shows” is neutral, objective, and defensible.
Frame it as a gap in care, not a failing.
The members managing the most complex medication regimens are also carrying the most clinical complexity. They deserve a physician who has the full picture. Positioning polypharmacy review as a care improvement, not a cost-cutting measure will keep the conversation constructive and keep the physician relationship intact.
Tie it to the costs your client can already see.
If pharmacy spend is rising as a share of total healthcare cost, and for most employers it is, now accounting for over 27% of total healthcare spend according to the Business Group on Health’s 2025 Employer Health Care Strategy Survey, up from 21% two years prior. The problem is addressable because polypharmacy is a logical, data-backed starting point.
Point to the physician as the solution.
The good news in this conversation is that there’s a trusted, credentialed party already embedded in the member relationship who can act on this: the prescriber. Solutions that route medication review information directly to the physician without requiring member action or app downloads to sidestep the engagement problem entirely.
The Timing Is Right
The risk is recognized and growing as a priority across the industry. CMS introduced new Part D Star Measures for 2025 specifically targeting polypharmacy with anticholinergic medications in older adults. The Department of Labor proposed new PBM transparency rules in January 2026, with projected savings tied in part to improved medication adherence. Employers and health plans are actively expanding deprescribing programs.
The infrastructure for this conversation already exists. What’s been missing is someone willing to start it.
The conversation nobody wants to start is the one with the most upside. The data is already there. The physician relationship is already there. The only thing missing is the right framing—and now you have it.
